Connect your AI

Vera Therapeutics VERA Software and Technology Licenses, Net

Software and Technology Licenses, Net at other companies

Vertex PharmaceuticalsVRTX

——

Travere Therapeutics, Inc.TVTX

——

Aurinia PharmaceuticalsAUPH

——

Nektar TherapeuticsNKTR

——

Viridian Therapeutics, Inc.VRDN

——

ImmunomeIMNM

——

Other financials

Income statement

Operating income-$125.1M-119%

Net income-$121.0M-134%

EPS (diluted)-$1.69-109%

Balance sheet

Cash & equivalents$114.4M+108%

Total debt$75.0M+37.8%

Total equity$499.7M-6.6%

Total assets$621.7M+1.9%

Cash flow

Operating cash flow-$106.5M-95.8%

CapEx$23.0K-87.7%

Free cash flow-$106.5M-95.1%

Valuation

Market cap$2.74B+87.5%

Enterprise value$2.7B+85.0%

Returns & leverage

Return on equity-71.3%+296pp

Debt / equity0.2×0.0×

Current ratio13.6×-14.0×

Where this comes from

Reported directly by Vera Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:OtherAssetsNoncurrent.

The official record: Vera Therapeutics’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Vera Therapeutics's software and technology licenses, net.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Harbor at dusk

Questions, answered.

What is Vera Therapeutics's software and technology licenses, net?: Vera Therapeutics (VERA) reported software and technology licenses, net of $5.94M in Q1 2026.